{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/prescribing-information/emollients/","result":{"pageContext":{"chapter":{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients","depth":2,"htmlHeader":"<!-- begin field acc4b8ec-c4de-467d-b488-0c4c28cc0c09 --><h2>Emollients</h2><!-- end field acc4b8ec-c4de-467d-b488-0c4c28cc0c09 -->","summary":"","htmlStringContent":"<!-- begin item 360726fd-6332-4162-82b4-a93a01cb034a --><!-- end item 360726fd-6332-4162-82b4-a93a01cb034a -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b956af26-604a-5c3f-b683-ca36e9f14fe8","slug":"available-products","fullItemName":"Available products","depth":3,"htmlHeader":"<!-- begin field 3e53aeab-afbb-4d0d-a540-38f84ed24984 --><h3>Which emollient products are available?</h3><!-- end field 3e53aeab-afbb-4d0d-a540-38f84ed24984 -->","summary":"","htmlStringContent":"<!-- begin item bd58e565-d728-4236-b150-07fa2d67e4c6 --><!-- begin field fc04ad61-a7ab-49c9-8b78-8b7bd25d93cb --><ul><li><strong>There are a large number of emollients available in the UK, including </strong>creams, ointments, gels, lotions, sprays, washes, and bath and shower additives, available as non-proprietary and/or proprietary products.<ul><li>For a complete list of all the emollient products available in the UK, see the British National Formulary (<a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"c4b9fc5e-eb46-40bb-819d-a8f7014e5df3\">BNF</a>).</li></ul></li><li><strong>Most emollient products are plain (that is, contain no active ingredients).</strong><ul><li><strong>However, some emollients contain:</strong><ul><li>Urea (a keratin softener and hydrating agent), for example Aquadrate<sup>®</sup>, Balneum<sup>® </sup>Plus, Calmurid<sup>®</sup>, E45<sup>® </sup>Itch Relief Cream, and Eucerin<sup>® </sup>Intensive.</li><li>Lauromacrogols (which have local anaesthetic properties, and soothes and relieves itchy skin), for example Balneum<sup>® </sup>Plus and E45<sup>® </sup>Itch Relief Cream.</li><li>Lanolin or lanolin derivatives, for example hydrous ointment, E45<sup>® </sup>cream and lotion, and Oilatum<sup>® </sup>emollient bath additive.</li><li>Antiseptic, for example Dermol<sup>® </sup>preparations (cream, lotion, shower, and bath emollient), Emulsiderm<sup>® </sup>liquid emulsion, and Oilatum Plus bath additive<sup>®</sup>.</li></ul></li><li>Emollients containing active ingredients are not generally recommended because they increase the risk of skin reactions. However, they may be useful in some people.</li></ul></li><li><strong>All emollients are available on the NHS, but some are classified as borderline substances and as such their prescriptions should be endorsed with 'ACBS' (Advisory Committee on Borderline Substances).</strong> These include Aveeno<sup>® </sup>products (bath oil, cream, and lotion) and E45<sup>® </sup>products (emollient bath oil, emollient wash cream, and lotion).<ul><li>Preparations marked ‘ACBS’ are regarded as drugs when prescribed in accordance with the advice of the ACBS for the clinical conditions listed. See the <a href=\"http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx\" data-hyperlink-id=\"43d667e8-2998-416a-9dee-a8f7014e5df3\">Drug Tariff </a>for more information.</li></ul></li><li><strong>Emollients are also available over-the-counter although availability may be limited.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BNF 72, 2016</a>]</p><!-- end field fc04ad61-a7ab-49c9-8b78-8b7bd25d93cb --><!-- end item bd58e565-d728-4236-b150-07fa2d67e4c6 -->","subChapters":[]},{"id":"f141b61b-8cf2-5beb-a14a-51d5099f0311","slug":"choice-of-product","fullItemName":"Choice of product","depth":3,"htmlHeader":"<!-- begin field 2b3eaf73-2ff4-424d-9123-e1b3421179fc --><h3>Which emollient product should I prescribe?</h3><!-- end field 2b3eaf73-2ff4-424d-9123-e1b3421179fc -->","summary":"","htmlStringContent":"<!-- begin item 2a540898-1eab-4616-93d0-a357851a24d5 --><!-- begin field 46488480-ffa4-4147-b6b7-91939da60b1b --><ul><li><strong>There is no evidence from controlled trials to support the use of one emollient over another </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">van Zuuren, 2017</a>]<strong>.</strong></li><li><strong>Prescribe an emollient according to the dryness of the skin, and individual preference/tolerance. </strong>The key to successful management is finding the correct balance between these factors.<ul><li>Creams and lotions are generally better for red, inflamed areas of skin because it is believed that the evaporation of water-based products cools the skin.</li><li>Ointments are preferable for dry skin (that is not inflamed) because they are more effective than creams. However, they are usually poorly tolerated compared with cream; this may affect their acceptability and hence compliance.</li><li>Experience has shown that proprietary products are often preferred to non-proprietary products; it may be a false economy to prescribe solely on the basis of price.</li><li>Often, several different emollients will be required (for example for different areas of skin, different stages of flare, or for use in different locations).</li><li><strong>Do not prescribe aqueous cream as it is thought to cause a disproportionate amount of skin reaction. </strong>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/#adverse-effects\">Adverse effects</a> for more information.</li></ul></li><li><strong>Where possible, prescribe an emollient with a pump dispenser to minimize the risk of bacterial contamination.</strong><ul><li>For emollients that come in pots, advise that using a clean spoon or spatula (rather than fingers) to remove the emollient helps to minimize contamination.</li></ul></li><li><strong>Emollients containing <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/#available-products\">active ingredients</a> are not generally recommended </strong>because they increase the risk of skin reactions, and the evidence to support the use of active ingredients in emollients is limited. However, they may be useful in some people. For example, products containing:<ul><li>Lauromacrogols are reputed to relieve itch.</li><li>Urea may improve skin hydration. It can enhance the moisture-retaining ability of emollients, thereby improving their efficacy.</li><li>Antiseptics (for example benzalkonium chloride) have a limited role in protecting skin which is prone to infection.</li></ul></li><li><strong>Prescribe emollients to replace soap in people with dry skin requiring treatment.</strong><ul><li>Ointments dissolved in hot water are suitable soap substitutes.</li><li>Bath additives and shower products are an option for people with extensive areas of dry skin, although the evidence to support their use is limited and there is no universal consensus on their benefit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">DTB, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>]. </li><li>If bath emollients are used, it is essential that they do not replace standard emollients. The person should be advised to continue using standard emollients in addition to any bath emollient product.</li></ul></li><li><strong>The effectiveness and acceptability of a particular emollient may vary with time.</strong><ul><li>If the person feels that a particular product has become unsuitable for them (or if they have developed sensitivity to it), prescribe an alternative emollient.</li><li>It may be necessary to try a range of emollients before the person settles on the best combination.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">National Collaborating Centre for Women's and Children's Health, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>]</p><!-- end field 46488480-ffa4-4147-b6b7-91939da60b1b --><!-- end item 2a540898-1eab-4616-93d0-a357851a24d5 -->","subChapters":[]},{"id":"241a24a2-8dd8-5524-8ac9-2aee501149d0","slug":"quantity","fullItemName":"Quantity","depth":3,"htmlHeader":"<!-- begin field f19b46e9-f020-475d-a342-ea869e02d71f --><h3>How much emollient should I prescribe?</h3><!-- end field f19b46e9-f020-475d-a342-ea869e02d71f -->","summary":"","htmlStringContent":"<!-- begin item b4e8ce87-5a1e-43b4-b920-77b5c72d21f8 --><!-- begin field 191c3265-0bb3-4953-a2cc-44b9e464cc60 --><ul><li><strong>Emollients are typically under-prescribed and under-used. This results in suboptimal treatment of dry skin and eczema, and may increase the occurrence of flares </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]<strong>.</strong></li><li>Once the preferred <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/#quantity\">choice</a> of emollient is known, encourage appropriate usage by prescribing generous amounts (for example 500 g) to be used regularly (often four times daily).</li><li>Where possible, pump-dispensers should be prescribed when large quantities of cream or lotion are required. This is because they are more convenient than other containers and are less likely to become contaminated by potential pathogens.</li><li>The amount of emollient used should far exceed other topical treatments (for example corticosteroids) by a factor of at least ten.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>]</p><!-- end field 191c3265-0bb3-4953-a2cc-44b9e464cc60 --><!-- end item b4e8ce87-5a1e-43b4-b920-77b5c72d21f8 -->","subChapters":[]},{"id":"58f66430-ad92-5263-8de4-e065000fe0cb","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field fdd49438-9242-460b-893e-427b4e7633ea --><h3>What are the adverse effects of emollients?</h3><!-- end field fdd49438-9242-460b-893e-427b4e7633ea -->","summary":"","htmlStringContent":"<!-- begin item 8653b4f5-94de-4e92-87ec-d7bf43d5f6fd --><!-- begin field 956a2ff5-4ee4-47c4-b5ed-4e3006800b51 --><ul><li><strong>Skin reactions are the most common adverse effects of emollients.</strong> They are caused by sensitivity of the skin to additives in the emollient, such as perfumes, preservatives, and biological components, such as lanolin (although newer hypoallergenic formulations of lanolin are less problematic).</li><li><strong>If a skin reaction occurs, </strong>stop the emollient and use a different one.</li><li><strong>If the person has had previous skin reactions to emollients, </strong>consider testing a small quantity on the skin before widespread application.</li><li><strong>If sensitivity to emollients is a known problem,</strong> prescribe a cream with few additives, or an ointment (ointments do not require preservatives and generally have less excipients), to reduce the chance of a further reaction.</li><li><strong>The occlusive effect of ointments can cause folliculitis. If this occurs, </strong>stop the ointment (consider switching to a cream), and prescribe an antibiotic, if necessary.</li><li><strong>Aqueous cream is generally not recommended because of the high risk of developing skin reactions.</strong><ul><li>A clinical audit found that the use of aqueous cream results in a significant proportion of people developing sensitization reactions, so it should be avoided [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Cork et al, 2003</a>].</li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) warns that aqueous cream may cause local skin reactions, such as stinging, burning, itching, and redness, when it is used as a leave-on emollient, especially in children with atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">MHRA, 2013</a>]. The reactions, which are not generally serious, often occur within 20 minutes of application but can occur later, and may be due to sodium lauryl sulfate or other additives [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">MHRA, 2013</a>].</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>] </p><!-- end field 956a2ff5-4ee4-47c4-b5ed-4e3006800b51 --><!-- end item 8653b4f5-94de-4e92-87ec-d7bf43d5f6fd -->","subChapters":[]},{"id":"429a7cea-3b43-5b98-a435-fd2d2bc41496","slug":"usage-instructions","fullItemName":"Usage instructions","depth":3,"htmlHeader":"<!-- begin field 112efb27-5bea-4c32-9777-6e0565dfb770 --><h3>What should I advise on how to use an emollient?</h3><!-- end field 112efb27-5bea-4c32-9777-6e0565dfb770 -->","summary":"","htmlStringContent":"<!-- begin item c32f6541-cea0-4f9e-b854-326175b88aeb --><!-- begin field c46e3a2e-648b-4c25-aada-f47a9272b516 --><p><strong>It is essential to provide instructions on the correct use of emollients, with clear demonstrations where appropriate.</strong></p><ul><li><strong>Advise the person t</strong><strong>o use emollients liberally and frequently, even when their skin appears improved or is clear.</strong><ul><li>It is recommended that 250–500 g of emollient be applied every week [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].</li><li>The frequency of application will vary depending on the person's condition and circumstances, but for very dry skin, application of an emollient every 2–3 hours should be considered normal.</li><li>To facilitate frequent application, the person should consider keeping separate packs of emollients at work or school.</li></ul></li><li><strong>Advise on the appropriate use of emollients.</strong><ul><li>It is particularly important to use emollients during or after washing. The skin should be gently dried and the emollient applied while the skin is still moist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Ng, 2015</a>]; experts believe this may help trap moisture in the skin.</li><li>Emollients should be applied by smoothing them into the skin along the line of hair growth, rather than rubbing them in.</li><li>It may be more convenient to use better tolerated products (such as creams and lotions) during the day, and ointments (which are usually poorly tolerated) at night.</li><li>If a topical corticosteroid is prescribed, they should wait several minutes after application of an emollient (about 15–30 mins if possible) before applying the topical corticosteroid [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>].</li><li>Emollient products should not be shared with other people as they can become contaminated with bacteria.<ul><li>Pump dispensers minimize the risk of bacterial contamination.</li><li>For emollients that come in pots, using a clean spoon or spatula (rather than fingers) to remove the emollient helps to minimize contamination.</li></ul></li></ul></li><li><strong>Also advise that:</strong><ul><li>They should avoid the use of soaps, detergents, and bubble bath when washing, as these have an emulsifying effect on the lipids of the skin and can be very damaging to the skin. Instead, a suitable soap substitute should be used, for instance an ointment dissolved in hot water (or lotion in warm water).</li><li>People who need to use large quantities (more than 100 g) of any paraffin-based product should regularly change clothing, bedding, or dressings which become impregnated with the product and keep away from naked flames, as there is a risk of fire [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">ABPI, 2016a</a>].</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">RCN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>]</p><!-- end field c46e3a2e-648b-4c25-aada-f47a9272b516 --><!-- end item c32f6541-cea0-4f9e-b854-326175b88aeb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}